More Than 450 Companies Drive Speed to Market with Veeva RIM

Rhea-AI Summary

Veeva Systems (NYSE:VEEV) announced significant adoption of its Regulatory Information Management (RIM) platform, now used by over 450 companies, including 19 of the top 20 biopharmas. The company has formed strategic partnerships with Accumulus Technologies and DNAnexus to enhance multi-health authority platform integration.

The platform's continuous publishing feature through Veeva Submissions Publishing is being utilized by more than 85 organizations to accelerate submission timelines. Accumulus's network connects over 70 regulatory agencies worldwide, while DNAnexus integration aims to improve inter-agency collaboration for faster product approvals.

Positive

• Strong market adoption with over 450 companies using Veeva RIM, including 19 of top 20 biopharmas
• Strategic partnerships with Accumulus Technologies and DNAnexus enhance platform capabilities
• 85+ organizations using continuous publishing feature for improved efficiency
• Access to Accumulus's network of 70+ regulatory agencies worldwide

Negative

• None.

Advanced regulatory capabilities and new industry partnerships accelerate collaboration with global health authorities

PLEASANTON, Calif., Sept. 2, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced more than 450 companies, including 19 of the top 20 biopharmas, have adopted Veeva RIM for regulatory information management (RIM) on a unified platform. Continued innovation to advance connectivity now includes partnerships with Accumulus Technologies and DNAnexus, enabling integration with multi-health authority platforms to drive efficiency and compliance.

"Regulatory teams are adopting new Veeva product innovations to continually improve efficiency and reduce cycle times. Strengthened by industry partnerships, Veeva RIM provides an end-to-end solution that accelerates time to market, improves global stakeholder collaboration, and enables seamless data flow in a rapidly evolving regulatory environment," said Marc Gabriel, vice president, regulatory at Veeva.

Companies using Veeva RIM applications can streamline processes across all steps of the regulatory lifecycle. With Veeva Submissions Publishing, more than 85 organizations are using continuous publishing to reduce rework and remove bottlenecks, accelerating submission timelines.

"Our strategic partnership will connect the Accumulus platform and Veeva RIM for greater interoperability to modernize how information is instantly and simultaneously shared with our growing network of over 70 regulatory agencies worldwide. By facilitating seamless regulatory submissions, we can empower our mutual customers to get treatments to patients faster," said Francisco Nogueira, CEO of Accumulus Technologies.

"Integrating DNAnexus Trusted Regulatory Spaces (TRS) and Veeva RIM will provide best-in-class data sharing capabilities for inter-agency collaboration and faster regulated product approvals," said Thomas Laur, CEO of DNAnexus.

Veeva RIM streamlines global regulatory processes on a single, cloud-based platform. It is part of Veeva Development Cloud, the technology foundation for product development across clinical, quality, regulatory, and safety. To learn more about Veeva RIM, visit veeva.com/RIM.

About Veeva Systems
Veeva delivers the industry cloud for life sciences with software, data, and business consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.

Veeva Forward-Looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended July 31, 2025, which you can find here (a summary of risks which may impact our business can be found on pages 33 and 34), and in our subsequent SEC filings, which you can access at sec.gov.

Contact:
Elizabeth McGrane
Veeva Systems
elizabeth.mcgrane@veeva.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/more-than-450-companies-drive-speed-to-market-with-veeva-rim-302542568.html

SOURCE Veeva Systems

FAQ

How many companies are currently using Veeva RIM platform?

More than 450 companies are using Veeva RIM platform, including 19 of the top 20 biopharma companies.

What new partnerships has Veeva Systems (VEEV) announced for RIM platform?

Veeva has partnered with Accumulus Technologies and DNAnexus to enable integration with multi-health authority platforms for improved efficiency and compliance.

How many organizations use Veeva Submissions Publishing for continuous publishing?

More than 85 organizations are using Veeva Submissions Publishing for continuous publishing to reduce rework and accelerate submission timelines.

What is the reach of Accumulus Technologies' regulatory network for Veeva RIM users?

Accumulus Technologies provides access to a network of over 70 regulatory agencies worldwide, enabling instant and simultaneous information sharing.

What is Veeva RIM's role in the Veeva Development Cloud?

Veeva RIM is part of Veeva Development Cloud, serving as the technology foundation for product development across clinical, quality, regulatory, and safety functions.